Instil Bio

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Instil Bio (TIL) a New Buy Stock

DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update.

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.

Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why

DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced a strategic update.

Instil Bio Announces Strategic Update

DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Thursday, December 7, 2023.

Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its third quarter 2023 financial results and provided a corporate update.

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

The heavy selling pressure might have exhausted for Instil Bio, Inc. (TIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)

ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facility with additional process improvements DALLAS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its second quarter 2023 financial results and provided a corporate update. “Successful manufacturing of ITIL-306 in our Manchester, UK facility is a major milestone on our path to clinical development of ITIL-306,” said Mark Dudley, Chief Scientific Officer of Instil Bio.

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its first quarter 2023 financial results and provided a corporate update. First Quarter 2023 Highlights and Anticipated Milestones: ITIL-306 phase 1 study in UK anticipated to initiate in 2H'2023: Instil has recently received positive initial feedback from the Medicines and Healthcare products Regulatory Agency, or MHRA, on the proposed study design for the phase 1 dose escalation study of ITIL-306 in the United Kingdom, and anticipates initiating such study in the second half of 2023 following anticipated Clinical Trial Application, or CTA, clearance from the MHRA.

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Company anticipates cash resources to provide runway beyond 2026

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site

Affimed

BioAtla, Inc

Eiger BioPharmaceuticals

Gracell Biotechnologies

Immuneering Corp

Nkarta, Inc.

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

7 Cheap But Risky Biotech Stocks

Context Therapeutics LLC

Kronos Bio

Ocugen, Inc.

Sonnet BioTherapeutics

Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Penny Stocks To Watch This Week With Big News

Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Instil Bio, Inc. (TIL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 61.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL)

NEW YORK--( BUSINESS WIRE )--Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Instil Bio, Inc. (NASDAQ:TIL) (“Instil” or the “Company”). The investigations concern whether certain of the Instil's officers and directors breached their fiduciary duties to shareholders, by, among other things: (i) engaging in self-dealing; (ii) affirmatively approving transactions that harmed the Company; and (iii) failing to provide sufficient oversight of the Company's business practices.

Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)

Instil Bio, Inc. (TIL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 59.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Instil Bio, Inc. (TIL)

DALLAS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing next-generation tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced a reprioritization of its clinical programs to focus on development of its CoStAR-TIL product candidates.

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

Boston, Massachusetts--(Newsfile Corp. - November 21, 2022) - Block & Leviton is investigating Instil Bio, Inc. (NASDAQ: TIL) for potential securities law violations. Investors who have lost money in their Instil Bio, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/til.What is this all about?Before the market opened on October 31, 2022, Instil Bio, Inc. disclosed that it had notified the U.S.

Instil Bio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL

Los Angeles, California--(Newsfile Corp. - November 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil Bio" or "the Company") (NASDAQ: TIL) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced poster presentations of pre-clinical data and trial-in-progress for the ongoing ITIL-306 Phase 1 clinical trial using the CoStimulatory Antigen Receptor (CoStAR) platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), to be held from November 8-12, 2022.

News for Instil Bio Stock (TIL)